Association of Perfluoroalkyl and Polyfluoroalkyl Substances With Adiposity
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Importance: Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are ubiquitous synthetic chemicals that are suspected endocrine disruptors. Objectives: To determine the extent to which PFASs are associated with increases in weight and body size and evaluate whether a lifestyle intervention modifies this association. Design, Setting, and Participants: This prospective cohort study included 957 individuals who participated in the Diabetes Prevention Program trial, conducted from July 1996 to May 2001, and the Diabetes Prevention Program Outcomes Study, conducted from September 2002 to January 2014. Statistical analysis was conducted from September 1, 2017, to May 25, 2018. Interventions and Exposures: The initial lifestyle intervention consisted of training in diet, physical activity, and behavior modification, with the major goals of achieving 7% weight loss with subsequent maintenance and a minimum of 150 minutes per week of physical activity. Participants randomized to placebo received standard information about diet and exercise. A total of 6 plasma PFASs were quantified at baseline and 2 years after randomization, means were calculated from baseline and year 2 concentrations, and means were summed to assess total PFAS burden. Main Outcomes and Measures: Weight, waist circumference, and hip girth were measured at baseline and at scheduled visits. Results: Of the 957 participants, 625 (65.3%) were women and 731 participants (76.4%) were between 40 and 64 years of age; 481 participants were randomized to the lifestyle intervention and 476 participants were randomized to the placebo arm. The PFAS concentrations were not different by treatment arm and were similar to concentrations reported for the US population in 1999-2000. The association of PFAS and weight change differed by treatment. Each doubling in total PFAS concentration was associated with an increase of 1.80 kg (95% CI, 0.43-3.17 kg; P = .01) from baseline to 9 years after randomization for the placebo group but not the lifestyle intervention group (-0.59 kg; 95% CI, -1.80 to 0.62 kg; P = .34). Similarly, each doubling in PFAS was associated with a 1.03-cm increase in hip girth in the Diabetes Prevention Program trial for the placebo group (95% CI, 0.18-1.88 cm; P = .02) but not the lifestyle intervention group (-0.09 cm; 95% CI, -0.82 to 0.63 cm; P = .80). No associations were observed for changes in mean waist circumference. Conclusions and Relevance: Among adults at high risk for diabetes, higher plasma PFAS concentration was associated with increases in weight and hip girth over time, but a lifestyle intervention attenuated these associations. Diet and exercise may mitigate the obesogenic effects of environmental chemicals. Trial Registration: ClinicalTrials.gov Identifier: NCT00004992 and NCT00038727.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Estimation of Average Concentration in the Presence of Nondetectable Values
Hornung, R. W., & Reed, L. D. (1990) · Applied Occupational and Environmental Hygiene · doi:10.1080/1047322x.1990.10389587 · Cited by 3,495
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Global Distribution of Perfluorooctane Sulfonate in Wildlife
Giesy, J. P., & Kannan, K. (2001) · Environmental Science & Technology · doi:10.1021/es001834k · Cited by 2,750
Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., Butenhoff, J. L., & Zobel, L. R. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10009 · Cited by 2,049
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Calafat, A. M., Wong, L.-Y., Kuklenyik, Z., Reidy, J. A., & Needham, L. L. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10598 · Cited by 1,247
Self-citation(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Trends in Exposure to Polyfluoroalkyl Chemicals in the U.S. Population: 1999−2008
Kato, K., Wong, L.-Y., Jia, L. T., Kuklenyik, Z., & Calafat, A. M. (2011) · Environmental Science & Technology · doi:10.1021/es1043613 · Cited by 777
Self-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Fluorinated Compounds in U.S. Fast Food Packaging
Schaider, L. A., Balan, S. A., Blum, A., Andrews, D. Q., Strynar, M. J., Dickinson, M. E., Lunderberg, D. M., Lang, J. R., & Peaslee, G. F. (2017) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.6b00435 · Cited by 620
Nelson, J. W., Hatch, E. E., & Webster, T. F. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901165 · Cited by 538
Self-citationThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Elosua, R., Molina, L., Fito, M., Arquer, A., Sanchez-Quesada, J. L., Covas, M. I., Ordoñez-Llanos, J., & Marrugat, J. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00018-2 · Cited by 286
Dreyer, A., Weinberg, I., Temme, C., & Ebinghaus, R. (2009) · Environmental Science & Technology · doi:10.1021/es9010465 · Cited by 230
Borg, D., Lund, B.-O., Lindquist, N.-G., & Håkansson, H. (2013) · Environment International · doi:10.1016/j.envint.2013.05.009 · Cited by 155
Polyfluorinated Compounds in Serum Linked to Indoor Air in Office Environments
Fraser, A. J., Webster, T. F., Watkins, D. J., Nelson, J. W., Stapleton, H. M., Calafat, A. M., Kato, K., Shoeib, M., Vieira, V. M., & McClean, M. D. (2012) · Environmental Science & Technology · doi:10.1021/es2038257 · Cited by 127
Self-citation
Cited by
Endocrine-disrupting chemicals: Implications for human health
Kahn, L. G., Philippat, C., Nakayama, S. F., Slama, R., & Trasande, L. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30129-7 · Cited by 797
Meneguzzi, A., Fava, C., Castelli, M., & Minuz, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706352 · Cited by 174
“No associations were observed for changes in mean waist circumference (56).”
BackgroundPolycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment
Parker, J., O’Brien, C., Hawrelak, J., & Gersh, F. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031336 · Cited by 114
Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment
parker, J., O'Brien, C., Hawrelak, J., & Gersh, F. (2021) · doi:10.20944/preprints202112.0088.v1 · Cited by 113
Perfluoroalkyl/polyfluoroalkyl substances: Links to cardiovascular disease risk
Schlezinger, J. J., & Gokce, N. (2024) · Circulation Research · doi:10.1161/circresaha.124.323697 · Cited by 103
Metadata
- Authors
- Cardenas, A., Hauser, R., Gold, D. R., Kleinman, K. P., Hivert, M.-F., Fleisch, A. F., Lin, P.-I. D., Calafat, A. M., Webster, T. F., Horton, E. S., & Oken, E.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2018-08-31
- Volume
- 1
- Issue
- 4
- Pages
- e181493
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2888783191
- Cited by
- 89
- References
- 20
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.